Compare TRTX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | RLMD |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.4M | 661.9M |
| IPO Year | N/A | 2012 |
| Metric | TRTX | RLMD |
|---|---|---|
| Price | $8.40 | $6.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.83 | ★ $12.40 |
| AVG Volume (30 Days) | 698.7K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $7.57 | $0.55 |
| 52 Week High | $9.85 | $8.00 |
| Indicator | TRTX | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 42.80 |
| Support Level | $8.35 | $6.17 |
| Resistance Level | $8.72 | $7.34 |
| Average True Range (ATR) | 0.15 | 0.45 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 30.61 | 1.75 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.